Anti-cancer activity and mechanism of flurbiprofen organoselenium compound RY-1-92 in non-small cell lung cancer-Reference-Cited by-同舟云学术

Anti-cancer activity and mechanism of flurbiprofen organoselenium compound RY-1-92 in non-small cell lung cancer

Published:2024 Issue:5 Volume:15 Page:1737-1745
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Cui Bo¹,Cheng Xianda¹,Zhang Xin¹,Chen Lili¹²³,Pang Wenqian¹,Liu Yue¹,Yang Zhe¹^ORCID,Li Hui¹,He Xianran⁴,Li Xiaolong⁵,Bi Xiuli¹²^ORCID

Affiliation:

1. College of Life Science, Liaoning University, Shenyang, 110036, China

2. Shenyang Key Laboratory of Chronic Disease Occurrence and Nutrition Intervention, College of Life Sciences, Liaoning University, Shenyang, 110036, China

3. College of Mathematics and Statistics, Liaoning University, Shenyang, 110036, China

4. Institute for Interdisciplinary Research, Jianghan University, Wuhan Economic and Technological Development Zone, Wuhan 430056, China

5. Shenzhen Fushan Biological Technology Co., Ltd, Kexing Science Park A1 1005, Nanshan Zone, Shenzhen 518057, China

Abstract

Flurbiprofen organic selenium compound RY-1-92 has anticancer activity in non-small cell lung cancer by targeting TRPV1 and its downstream MAPK signaling.

Funder

China Postdoctoral Science Foundation

Liaoning Revitalization Talents Program

Department of Education of Liaoning Province

Liaoning University

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00058G

Reference31 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer

3. Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

4. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

5. On the pharmacogenetics of non-small cell lung cancer treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer;International Journal of Molecular Sciences;2024-06-01